Premium
Recombinant Mycobacterium smegmatis Expressing an ESAT6‐CFP10 Fusion Protein Induces Anti‐Mycobacterial Immune Responses and Protects Against Mycobacterium tuberculosis Challenge in Mice
Author(s) -
Zhang H.,
Peng P.,
Miao S.,
Zhao Y.,
Mao F.,
Wang L.,
Bai Y.,
Xu Z.,
Wei S.,
Shi C.
Publication year - 2010
Publication title -
scandinavian journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.934
H-Index - 88
eISSN - 1365-3083
pISSN - 0300-9475
DOI - 10.1111/j.1365-3083.2010.02448.x
Subject(s) - mycobacterium smegmatis , mycobacterium tuberculosis , recombinant dna , fusion protein , antigen , vaccination , tuberculosis , immune system , virology , spleen , titer , cytotoxic t cell , microbiology and biotechnology , bcg vaccine , biology , antibody , immunology , medicine , in vitro , gene , biochemistry , pathology
The currently used vaccine against tuberculosis, Bacille Calmette‐Guérin (BCG), has variable efficacy, so new vaccine development is crucial. In this study, we evaluated a recombinant vaccine prepared from non‐pathogenic Mycobacterium smegmatis (rMS) that expresses a fusion of early secreted antigenic target 6‐kDa antigen (ESAT6) and culture filtrate protein 10 (CFP10). C57BL/6 mice were immunized with the rMS expressing the ESAT6‐CFP10 fusion protein (rM.S‐e6c10) or with BCG. The mice in the rM.S‐e6c10 group had a significantly higher titre of anti‐ESAT6‐CFP10 antibodies than did animals in the BCG or saline groups. Spleen cells from rM.S‐e6c10‐immunized mice exhibited a cytotoxic response to ESAT6 and CFP10‐expressed target cells, but spleen cells from animals in the other groups did not. Levels of IFN‐γ and IL‐2 production by purified T cells from spleens were significantly higher in rM.S‐e6c10 group than in BCG group. Finally, after M. tuberculosis (MTB)‐challenged mice, dramatic reduction in the numbers of MTB colony‐forming units (CFUs) in the lungs was observed for the mice immunized with the rMS. The protective efficacy of rM.S‐e6c10 and BCG vaccination was similar based on measures of MTB burden and lung pathology. Our data indicate that the recombinant M. smegmatis vaccine expressing the ESAT6‐CFP10 fusion protein has potential in clinic application.